A cancer drug recall has been initiated due to reports of excessive levels of an active ingredient used in the drug.
Pharmaceutical company AstraZeneca UK has initiated the recall, primarily for batch NG327, because the “level of olaparib polymorphic form L exceeds the registered specification limit”.
As well as the batch being recalled above, there are other batches that are a part of the recall as well, which is all said to be a part of a precautionary measure.
Continue Reading…